Home › Funds › Boussard & Gavaudan Investment Management LLP › HALO

Boussard & Gavaudan Investment Management LLP position in HALO

HALOZYME THERAPEUTICS INC · Health Care

Boussard & Gavaudan Investment Management LLP reported holding 2,100 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q1 2026 13F filing — a position valued at US$2.7M, representing 0.29% of its reported portfolio and ranking #45 among its reported holdings. Boussard & Gavaudan Investment Management LLP has disclosed HALO holdings in 6 of the last 11 reported quarters, going back to Q3 2023.

Latest position (Q1 2026)2.10K sh
Reported value held$2.67M
Portfolio Weight0.29%
First reportedQ3 2023
Last changeNew
Updated2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

How Boussard & Gavaudan Investment Management LLP's HALO position evolved

Boussard & Gavaudan Investment Management LLP first disclosed a stake in HALO in Q3 2023 at 21,964 shares (US$859K). The position peaked in Q2 2025 at 35,200 shares, worth US$35.2M. Across 6 filings, Boussard & Gavaudan Investment Management LLP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q1 2026) shows 2,100 shares valued at US$2.7M. Notable position changes include a 135% increase in Q2 2025 (shares rose 41% over the following quarter), a 94% trim in Q3 2025 (shares fell 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 21.96K $858.57K New
Q3 2024 12.50K $12.56M New
Q1 2025 15.00K $15.87M New
Q2 2025 35.20K $35.17M Add
Q3 2025 2.10K $2.97M Reduce
Q1 2026 2.10K $2.67M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$196.5M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has Boussard & Gavaudan Investment Management LLP held HALO?

Boussard & Gavaudan Investment Management LLP has disclosed HALO holdings in 6 of the last 11 reported quarters, going back to Q3 2023.

What is Boussard & Gavaudan Investment Management LLP's current position in HALO?

As of Q1 2026, Boussard & Gavaudan Investment Management LLP holds 2.10K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $2.67M, representing 0.29% of its reported portfolio and ranking #45.

Has Boussard & Gavaudan Investment Management LLP been buying or selling HALO?

In the latest 13F filing (Q1 2026), Boussard & Gavaudan Investment Management LLP newly opened its position in HALO. The position peaked in Q2 2025 at 35.20K shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.